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Resistance mutationsFibroblast growth factor receptors (FGFRs) are recognized therapeutic targets in cancer. We here describe
insights underpinning the impact of mutations on FGFR1 and FGFR3 kinase activity and drug efﬁcacy, using a
combination of computational calculations and experimental approaches including cellular studies, X-ray crys-
tallography and biophysical and biochemical measurements. Our ﬁndings reveal that some of the tested
compounds, in particular TKI258, could provide therapeutic opportunity not only for patients with primary alter-
ations in FGFR but also for acquired resistance due to the gatekeepermutation. The accuracy of the computational
methodologies appliedhere shows a potential for theirwider application in studies of drug binding and in assess-
ments of functional and mechanistic impacts of mutations, thus assisting efforts in precision medicine.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
Fibroblast growth factors and their receptors (FGFs and FGFRs) play
a critical role inmany physiological processes including embryogenesis,
wound healing, inﬂammation and angiogenesis as well as adult tissue
homeostasis (Beenken and Mohammadi, 2009). Compelling evidence
also implicates activation of FGFRs (FGFR1–4) in pathogenesis of several
developmental syndromes and a broad range of human malignancies.
FGF/FGFR signalling contributes to tumour generation and progression
through activating FGFR genomic alterations (driver point-mutations,
fusions and ampliﬁcations) (Greulich and Pollock, 2011; Wesche et al.,
2011; Sabnis and Bivona, 2013), as a positive regulator of tumour
neoangiogenesis (Turner and Grose, 2010) and as a mediator of resis-
tance to endocrine (Turner et al., 2010) and targeted therapies to relat-
ed oncogenic pathways, in particular to signalling by other receptor
tyrosine kinases such as epidermal growth factor receptor (EGFR)
(Wilson et al., 2012; Crystal et al., 2014).
The involvement of FGF/FGFRs in the pathology of many cancer
types provides a strong rationale for development of effective agents.v.coveney@ucl.ac.uk
. This is an open access article underfor these targets and a large effort to develop FGFR inhibitors as antican-
cer treatments is underway (Brooks et al., 2012; Dieci et al., 2013). Some
of the FGFR inhibitors such as TKI258 (dovitinib), levatinib, brivanib and
AP24534 (ponatinib) also target a subset of other tyrosine kinaseswhile
AZD4547, PD173074, BGJ398 and JNJ-*493 appear to be selective for
FGFR1–3. For the compounds already in clinical trials, important issues
include optimising the management of emerging toxicity proﬁles and
anticipated intrinsic target resistance as well as designing further trials
to best match the target alterations with the proposed drug action.
One of the bottlenecks in achieving such precision therapies is the lack
of suitable approaches to functionally interpret vast quantities of geno-
mic data. In particular, for FGFRs there are hundreds of mutations found
in tumour samples (Greulich and Pollock, 2011; Wesche et al., 2011;
Sabnis and Bivona, 2013) and their impact on FGFR activation cannot
be predicted based on crystallographic insights alone; this is in part
due to the considerable scope for allosteric effects inherent to protein
kinases (Meharena et al., 2013).
Furthermore, the inhibitor binding can also be altered by various
mutations. Prime examples are acquired intrinsic resistance mutations
that have marred the success of tyrosine kinase inhibitors (TKIs) such
as geﬁtinib, erlotinib and imanitib, prompting efforts for second- and
third-line treatments (Daub et al., 2004; Azam and Daley, 2006;
Gibbons et al., 2012). One resistance mechanism common to manythe CC BY license (http://creativecommons.org/licenses/by/4.0/).
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that remains the most frequently detected drug-resistance mutation
in the clinic. Examples include resistance to TKIs targeting breakpoint
cluster region-abelson tyrosine kinase (BCR-ABL) fusion in chronic
myelogenous leukaemia (Gorre et al., 2001; Shah et al., 2002), EGFR in
nonsmall cell lung cancer (Kobayashi et al., 2005; Pao et al., 2005),
platelet-derived growth factor receptor (PDGFR) in hypereosinophilic
syndrome (Cools et al., 2003), KIT in gastrointestinal stromal tumours
(Tamborini et al., 2006) and echinoderm microtubule-associated
protein-like 4-anaplastic lymphoma kinase (EML4-ALK) fusion in lung
cancer (Choi et al., 2010b). Modelling in cell culture has also been suc-
cessfully used to discover clinically relevant acquired resistance and
the application of this approach to FGFR driven-cancer cells identiﬁed
a gatekeeper substitution (Chell et al., 2013). Gatekeeper substitutions
in FGFR have been also identiﬁed in clinical samples, however as prima-
ry cancer mutations rather than secondary mutations (Taylor et al.,
2009; Shukla et al., 2012; Ang et al., 2015). Taking into account the
widespread occurrence of acquired gatekeeper resistance in many
kinases and initial laboratory and clinical observations for FGFR, occur-
rence of this phenomenon in FGFR is widely anticipated.
Further factors that can inﬂuence drug binding include, pre-existing
mutations in the targeted kinase or subtle differences between closely re-
lated familymembers. This has also been documented for the FGFR family
members (Brooks et al., 2012;Dieci et al., 2013; Byron et al., 2013) empha-
sizing the need for further characterisation that would inform treatment.
Here we apply a combination of approaches to address current lim-
itations in assessing whether a speciﬁc mutation in a kinase domain af-
fects the activity or alters drug sensitivity.We report strikingdifferences
between FGFR sequence variants with respect to the effect on kinase
activity and the efﬁcacy of tyrosine kinase inhibitors. Furthermore, we
found that the gatekeeper variant, that enhances kinase activity, is not
refractory to some of the inhibitors currently in clinical trials; in partic-
ular, TKI258 retained its efﬁcacy towards FGFR1 and FGFR3 gatekeeper
substitutions in vitro and in cells. Theseﬁndings, supported bymeasure-
ments of kinase activity, determination of binding constants and X-ray
crystallography, are in good agreement with the values obtained inde-
pendently by molecular dynamics simulations that also provide an in-
depth insight into the allosteric communication between the mutated
site and important functional motifs. The computational methods used
here to calculate the binding and surface free energies could therefore
have wider application in predicting the functional impact of disease
mutations, drug binding and underpinning molecular mechanisms.
2. Methods
2.1. Protein Expression and Puriﬁcation
All kinase domain constructs were cloned into pOPINS (OPPF, Oxford,
UK) or pJ821 (DNA2.0, USA) and expressed in C41 (DE3) cells harbouring
lambda phosphatase and human CDC37. Kinases were puriﬁed by a com-
bination of Ni2+-chelating, ion exchange and gel ﬁltration chromatogra-
phy. Protein purity was assessed by SDS-PAGE and preparations at
N95% homogeneity were used for kinase assays and crystallography.
2.2. Kinase Assay
The ADP-Glo (Promega)methodology was used for all kinase assays
following manufacturers instructions. Unless otherwise stated in the
text, each kinase assay consisted of 20 μL, containing Kinase Buffer
(40 mM Tris-HCl, 20 mM NaCl, 20 mM MgCl2, 2 mM TCEP, 2 mM
MnCl2, Na3VO4, 0.1 mg/mL BSA, pH 8.0), 250 μM ATP, 0.4 mg/mL
polyGlu4Tyr substrate, 0.5 μM kinase domain and inhibitors in selected
experiments. In various experiments the concentrations of these com-
ponents were varied and this is stated in the text or ﬁgure legends. In
order to calculate valid inhibition constants (Ki), a number of kinetic pa-
rameters needed to be ascertained, in particular, the Km of the kinasesfor ATP. A thorough Michaelis–Menten kinetic analysis was performed
ensuring that all relevant parameters were in the linear range and that
the appropriate concentrations of ATP, substrate and kinase were ad-
hered to. All datawere processed usingGraphpad Prismand parameters
presented in Supplemental Tables. Classical enzyme competitive inhibi-
tion approacheswere found to be unsuitable to generate inhibition con-
stants and therefore the Morrison approach (the quadratic velocity
equation for tight-binding substrates) was utilized (Morrison, 1969).
2.3. Crystallisation and Crystallography
Crystals of FGFR1-2c Apo, native FGFR1-2c with TKI258 (FGFR1-2c
TKI258) and FGFR1-2cV561M with TKI258 (FGFR1-2cV561M TKI258)
were grown by both hanging and sitting drop methods in condition
20% PEG 5 K MME, 0.1 M Tris, pH 7.5, 0.2 M ammonium sulphate. X-
ray diffraction data were recorded at Diamond Light Source in stations
I02, I03 and I24 for FGFR1-2c Apo, FGFR1-2c TKI258 and FGFR1-
2cV561M TKI258 respectively. The data were auto-processed using
autoprocessing tools Xia2 (Winter et al., 2013) and FAST_DP (uses
XDS (Kabsch, 2014)) at Diamond Light Source. The unmerged output
from XDS was taken for each of the dataset and scaled using Aimless
(Evans and Murshudov, 2013) software suite from CCP4 package
(Winn et al., 2011). The FGFR1-2c Apo, FGFR1-2c TKI258 and FGFR1-
2cV561M TKI258 were scaled to a high resolution of 2.3 Å, 1.96 Å and
1.96 Å units respectively. Please refer to Supplemental Table S5, X-ray
data processing statistics. Phasing, reﬁnement and structure validation
are described in the Supplemental Material.
2.4. Computational Calculations
The binding and the surface free energy changes were calculated
usingmultiple thermodynamic integration simulations based onmeth-
odology described in (Wan and Coveney, 2011). Further improvements
and enhanced-sampling molecular dynamic simulations (parallel-tem-
pering metadynamics) were according to (Bussi et al., 2006); the algo-
rithms were previously used in calculating the conformational free
energy surfaces of EGFR (Sutto and Gervasio, 2013), c-SRC and ABL
(Lovera et al., 2012). Computational calculations are described further
in Supplemental Material.
2.5. PDB ID Codes
The reﬁned and validated structures of FGFR1-2c Apo, FGFR1-2c
TKI258 and FGFR1-2cV561M TKI258 have been submitted to Protein
Data Bank (PDB) and their PDB ID codes are 4UWY, 4UWZ and 4UX0,
respectively.
3. Results
3.1. Kinase Activity and Inhibition of FGFR Variants by Non-selective and
Selective Inhibitors
Mutations in the ATP binding pocket of protein kinases that prevent
or reduce binding of inhibitory compounds most frequently occur at a
particular residue in the hinge region between the N and C lobes,
positioned to control access to a hydrophobic pocket that helps anchor
kinase inhibitors to the active site. This, so called, gatekeeper residue
corresponds to threonine in a number of kinases (including EGFR,
PDGFR, KIT, ABL and SRC) but can also be other amino acid residues
such as leucine, phenylalanine or valine (Fig. 1A). Among all FGFRmem-
bers, the gatekeeper valine is conserved, however, the tyrosine residue
in its proximity in FGFR1-3 corresponds to a cysteine in FGFR4
(Fig. 1A). FGFR4 is known to have reduced sensitivity to several inhibi-
tors and the position of the tyrosine to cysteine replacement (close to
the gatekeeper) is likely to contribute to such a difference. For the anal-
yses of inhibitor sensitivity, we focused on a structurally well-deﬁned
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Fig. 1. Kinase activity and inhibition of FGFR1 variants. A. Amino acid alignment of part of the hinge region of the FGFR family and a number of other tyrosine kinases with reported gate-
keepermutations. The gatekeeper residue in each case is numbered and bordered in dark grey. The FGFR 1 to 3 tyrosine that is a cysteine in FGFR4 is highlighted in light grey. B. Histogram
showing the inhibition constants (Ki) for four selected compounds upon FGFR1 kinase domain protein, wild type and the indicatedmutants. The datawere generated fromenzyme kinetic
analyses using various concentrations of inhibitors and ﬁtting using theMorrison equationwithin Graphpad Prism. Each data point was repeated in duplicate and the standard error of the
mean is presented on each bar. C. Left panel: comparison of the activity of FGFR1 apo (WT-apo) and phosphorylated (WT-2P) kinase domain protein produced using the ADP-Glo Assay.
Each data point was produced in triplicate and the standard errors are indicated. Right panel: comparison of the enzyme efﬁciency (kcat/Km) of FGFR1 apo and phosphorylated protein.
Parameters were generated through Michaelis–Menten kinetic experiments and analysed using Graphpad Prism software. D. Histogram showing the change in inhibition constants for
phosphorylated FGFRWT and apo and phosphorylated FGFR1V561Mwhen normalised to apo FGFR1WT values (taken as 100%) for the indicated inhibitors. The data in B–D are representative
for 3–4 independent experiments. See also Supplemental Tables S1 and S2.
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Norman et al., 2012), with the gatekeeper V561M variant and Y563C
variant (corresponding to the replacement found in FGFR4) generated
in the context of FGFR1.
TKI258 and AP24534 are among several pan-tyrosine kinase inhibi-
tors that include FGFR in their panel of targets. They are currently being
tested in preclinical and clinical studies for their anti-tumour activity
through the direct inhibition of FGFR (Andre et al., 2013; Konecnyet al., 2013; Motzer et al., 2014; Gozgit et al., 2012; Mazzola et al.,
2014). A selective FGFR1-3 inhibitor PD173074 has been widely used
in preclinical studies while AZD4547, that also selectively targets
FGFR, is in several phase I and phase II clinical trials (Ye et al., 2014;
Dutt et al., 2008; Lamont et al., 2011; Lei et al., 2014; Liu et al., 2014;
Ramsey et al., 2013; Xie et al., 2013; Dieci et al., 2013). Analysis of
these four inhibitors in an in vitro kinase assay showed that in addition
to the expected differences in their potency towards the WT FGFR1,
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iants (Fig. 1B, Supplemental Table S1). The Y563C replacement resulted
in reduced sensitivity to all tested inhibitors with the most pronounced
effect on inhibition by TKI258 (about 7-fold). Interestingly, the gate-
keeper mutation V561M resulted in a clear reduction of sensitivity to
PD173074 and AZD4547, a marginal effect on sensitivity to AP24534
and an increase in inhibition by TKI258 compared to wild type. Thus,
these two closely positioned point mutations have speciﬁc signatures
for inhibitor sensitivity. The data also show, that the gatekeeper muta-
tion, that would potentially result from treatment with compounds
such as PD173074 or AZD4547, has a similar or better response com-
pared to the WT to some other inhibitors that target FGFR, namely,
AP24534 and TKI258.
Further study of the V561Mgatekeepermutation examined how the
phosphorylation state of the FGFR1 KD affects sensitivity to the selected
inhibitors. Previous studies had identiﬁed phosphorylation of two tyro-
sine residues (Y653 and Y654) as the key step in the shift towards an ac-
tivated form of FGFR1 (Furdui et al., 2006).We generated this phospho-
form (WT-2P) of FGFR1 and conﬁrmed an increase in kinase activity
(Fig. 1C, Supplemental Table S2). Comparison of non-phospho and
phosphorylated forms of theWT and gatekeeper has shown that the rel-
ative change in potency of the inhibitorswas similar to that observed for
the non-phospho forms (Fig. 1D, Supplemental Table S1). The data also
show that the phospho form of the V561M variant was less sensitive to
all inhibitors with the sensitivity to TKI258 being similar to that ob-
served for the phospho WT (Ki values of 142.0 ± 15.7 and 121.2 ±
5.4, respectively; Supplemental Table 1).
We also compared actual Ki values for each inhibitory compound
(Fig. 1B, Supplemental Table S1). This shows that AZD4547, due to its
potency, could theoretically, be effective towards the gatekeeper substi-
tution evenwhen its Ki is increased (from6.1 nM to 82.1 nM). However,
further considerations involving parameters relevant for drug adminis-
tration (such as effective dose and side effects) or other consequences
that mutations could have on the global state of the harbouring cell,
need to be taken into account.
3.2. Effect of the Gatekeeper Mutation on Direct Binding of FGFR Inhibitors
The potency among the tested inhibitors on the gatekeeper variant
showed the biggest difference between PD173074 and TKI258, where
the change of up to 225-fold reduction contrasts to no change or even
higher efﬁcacy towards the non-phospho form (Supplemental
Table S1). To understand different binding modes that could underlie
the observed difference in inhibition, we performed theoretical calcula-
tions of binding free energies in parallel with direct experimental mea-
surements using ITC and structural analysis by X-ray crystallography.
The binding free energy change upon gatekeepermutationwas esti-
mated using multiple thermodynamic integration (TI) simulations in
both directions, i.e. alchemically mutating valine to methionine and
vice versa (Table 1). The experimental results of ITC measurements,Table 1
Binding free energy difference ΔΔGbinding = ΔGmutbinding− ΔGWTbinding (kcal/mol).
Simulation Energy Rep1 Rep2 Rep3 Rep4
FGFR1V561M with PD173074
Forward ΔGproteinalch 1.03 0.46 1.08 0.6
ΔGcomplexalch −2.90 −2.28 −3.28 −3.0
Reverse ΔGproteinalch 0.73 0.51 0.77 1.3
ΔGcomplexalch −2.35 −1.54 −1.95 −1.7
FGFR1V561M with TKI258
Forward ΔGproteinalch 1.03 0.46 1.08 0.6
ΔGcomplexalch 0.68 1.18 1.53 1.6
Reverse ΔGproteinalch 0.73 0.51 0.77 1.3
ΔGcomplexalch 1.48 1.39 1.84 0.6
Values in parentheses are uncertainties of the binding free energy changes. For calculation, they
they are standard deviations of repeated measurements.including Kd, ΔH, TΔS and ΔG, are shown in Supplemental Table S3.
For PD173074, the calculated binding free energy difference ΔΔG
(3.25 ± 0.42 kcal/mol) matches the experimental value (2.73 ±
0.18 kcal/mol) from ITC experiments. Both calculation and experiment
demonstrate that the gatekeeper mutation V561M in FGFR1 reduces
the binding afﬁnity for PD173074. The same approach was applied
to the binding of TKI258 and here again the calculated binding free en-
ergy difference and the experimental values were comparable (theoret-
icalΔΔG of−0.55±0.12 kcal/mol compared to experimental−0.60±
1.14 kcal/mol), showing somewhat better binding to the gatekeeper.
The accuracy of our TI simulations is further supported by another
example (free binding energy differences of PD173074 for the Y563C
variant) with good agreementwith experimental values (Supplemental
Tables S3 and S4). The comparison of experimental values and compu-
tational calculations is summarised in Fig. 2A.
Of the two inhibitors analysed in our theoretical study, only the
structure of PD173074 bound to the WT FGFR1 KD has been available
(Mohammadi et al., 1998). To extend the structural analysis, we solved
the structures of theWT FGFR1 KDwithout andwith bound TKI258 and
of FGFR1 KD V561M variant with TKI258 at 2.3, 1.96 and 1.96 Å resolu-
tion respectively (Supplemental Table S5). TKI258 binds in the hydro-
phobic pocket at the ATP-binding cleft and is stabilised by hydrogen
bonds, hydrophobic and van der Waals contacts (Fig. 2B and C, Supple-
mental Table S6A). The drug engages the enzyme with a total contact
area of ~60 Å2. Five hydrogen bonds (involving residues E562, A564
and S565) and 10 amino acid residues involved in hydrophobic interac-
tions provide a direct contact between WT FGFR1 and TKI258 and
stabilises the drug–protein complex (Fig. 2C and Supplemental
Fig. S1A). One water molecule is found to interact with atom N29 of
TKI258. The structures of TKI258 bound WT FGFR1 KD and FGFR1 KD
V561M superposes on apo WT FGFR1 KD with an overall root mean
square deviation (rmsd) value of 1.02 (287 amino acid residues) and
1.01 (286 amino acid residues) Å units, while the drug bound WT
FGFR1 KD and FGFR1 KD V561M superpose on each other with an
rmsd value of 0.36 Å units (293 amino acid residues) (Supplemental
Table S6C). The low rmsd values and illustrated superimposed struc-
tures in Fig. 2B (left and middle panel) suggest that the binding of
TKI258 to FGFR1 KD does not alter the enzyme structure.
TKI258 binds more tightly to the FGFR1 KD V561M (Ki ~35 nM)
while binding of PD173074 (Ki ~1580 nM) is greatly obstructed (Sup-
plemental Table S1); structural insights highlight the underpinning
differences (Fig. 2C). TKI258 binding is strengthened by the gatekeeper
residue,M561, at its binding site by increasing the number of hydropho-
bic contacts. The total number of van der Waals contacts for WT FGFR1
KD and FGFR1 KD V561M are 28 and 37, respectively. In addition,M561
pushes two water molecules and K514 out of the binding cleft, which
was observed in the TKI258-WT FGFR1 KD structure (Fig. 2B, right
panel and C, left and middle panels). Thus in the gatekeeper mutant,
the polar charge contribution of K514 and two water molecules are
void at the binding cleft leading to a stronger afﬁnity of TKI258 to theRep5 Average ΔΔGtheor ΔΔGtheoravg ΔΔGexp
0 0.96 0.83 3.66 3.25
(0.42)
2.73
(0.18)7 −2.63 −2.83
1 0.97 0.86 2.83
0 −2.31 −1.97
0 0.96 0.83 −0.43 −0.55
(0.12)
−0.60
(1.14)9 1.20 1.26
1 0.97 0.86 −0.66
6 2.22 1.52
are simply half the differences of the forward and reverse results, while for the experiment,
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TKI258 in FGFR1 KD V561M increases (with Sδ and Cε atoms from
M561) compared to V561 in WT FGFR1 KD. In contrast to TKI258, the
structure of PD173074 bound to the WT FGFR1 KD (PDB: 2FGI) shows
that the drug binds deep inside the ATP binding cleft and forms a very
strong hydrophobic interaction with M535 and V561 (Fig. 2C). M535
forms a lock-and-key type of interaction with the dimethoxy group of
the compound while the phenyl ring is well stabilised by a stacking in-
teraction from the gatekeeper residue V561. Consequently, PD173074
exhibits very weak afﬁnity (Supplemental Table S1) to the FGFR1V561M
gatekeeper mutant due to its close proximity to the gatekeeper residue
M561. The Sδ and Cε atoms of M561 in FGFR1V561M would cause steric
clashes with the phenyl ring and push the ligand away and out from
the binding pocket as the major contributing factor to greatly reduced
sensitivity to this inhibitor.
Further structural considerations based on differences between in-
active and active forms of FGFR1 and other FGFR KD structures (PDB:
3GQI, 2PY3, 2PVF, 2PSQ, 4K33) support the observed lower efﬁcacy of
TKI258 towards the phosphorylated, active form (Supplemental
Figs. S2 and S3). Upon stimulation FGFR KD undergoesmajor sequential
structural changes. These changes involve the movement of the N-lobe
towards the C-lobe of KD,, aligning of residues within the catalytic and
regulatory (hydrophobic) spines impact on “molecular brake” and the
opening of A- loop to accommodate ATP (PDB: 3GQI). As a consequence
the backbone and side chain atoms of FGFR residues that interact with
TKI258 show a signiﬁcant rearrangement. The result is a reduction in
accessible surface area for the ligand, leading to fewer/weaker hydrogen
bonding interactions and van der Waals contacts (Supplemental
Fig. S3).
3.3. Effect of the Gatekeeper Mutation on FGFR1 Kinase Activity
Analyses of gatekeeper threonine to bulkier side chain (methionine
or isoleucine) substitutions in other kinases, in particular in SRC and
EGFR, have shown that the mutations result in an enhancement of the
kinase activity (Azam et al., 2008). In FGFR kinases the corresponding
wild type amino acid residue is valine and replacement with a larger
hydrophobic residue could have a similar effect. Direct comparison of
the WT and V561M FGFR1 variants in an in vitro kinase assay shows
higher activity of the gatekeeper and a 6-fold increase of the kcat/Km
ratio for ATP (Fig. 3A). A spatially close Y563C substitution resulted in
the reduction of kinase activity (Supplemental Table S2).
The same conclusion, namely an increase in kinase activity of the
gatekeeper V561M variant, was independently reached using
enhanced-sampling parallel tempering metadynamics molecular dy-
namics (MD) simulations (Fig. 3B and C). Similar data were obtained
using TI simulations (Supplemental Table S7). Using these two well-
established methods for calculating free energies (TI simulations and
parallel tempering metadynamics), together with two of the best pro-
tein force ﬁelds (Amber ff99SBildn and CHARMM22*), we ﬁnd theoret-
ical agreementwith respect to the activating nature of themutation and
the associated mechanism of action. This information could not be ob-
tained based only on static crystal structures of the WT and gatekeeper
variants with TKI258.Fig. 2. Binding of FGFR-inhibitors to wild type (WT) and V561M FGFR1 KD. A. Histogram comp
imental (generated through ITC) difference in free energy of the indicated inhibitors binding to
ange) andWT FGFR1 KD bound to TKI258 (marine) (left panel) and superposition of TKI258-bo
shown as ribbon representations. Electron density map (2Fo-Fc) contoured at 1.0 σ for TKI258 i
coloured in magenta and forest green respectively. Several key residues, including DFG motif,
TKI258 bound to WT FGFR1 KD and FGFR1 KD V561M showing the gatekeeper residue V561
(2Fo-Fc) contoured at 1.0 σ is shown for the gatekeepr, DFGmotif and Lys514 residues. The solv
tron density map (2Fo-Fc) controured at 1.0 σ.C. Ball-and-stick representation of TKI258 bound
Key residues are shown and labelled. Electron density map (2Fo-Fc) contoured at 1.0 σ is sho
TKI258 is shown as red sphere. Hydrogen bonds are shown as black dashed lines. Fluoride ato
(PDB: 2FGI) and its interacting residues are shown in the right panel. In all panels DFGmotif is co
are coloured in salmon or green and residues involved in hydrophobic interaction and van derThe reconstruction of the fully converged free energy surface (FES)
of the activation transition shows a clear stabilizing effect of the muta-
tion on the active state of FGFR as compared to WT FGFR (Fig. 3B and
C). Indeed, the active state of the non-phosphorylated WT FGFR is a
high-energyminimum (ΔG ~5 kcal/mol). Themost stable conformation
corresponds to a partially deformed activation loop, resulting in a con-
formation intermediate between the active and the fully inactive one
that we refer to as semi-inactive; a similar semi-inactive state has re-
cently been reported in EGFR (Shan et al., 2012; Sutto and Gervasio,
2013). In contrast, the V561M mutation both stabilises the activation
loop in the open, fully active conformation by 4 kcal/mol with respect
to the WT FGFR, and lowers the free energy barrier between the two
states. The populations of the semi-inactive and active activation loop
conformations are similar in the case of the mutant, separated by a
relatively low (~3 kcal/mol) free energy barrier.
MD simulations also suggest the mechanism by which the methio-
nine allosterically induces a large shift in the energy landscape of the
FGFR1 KD. Consistent with the insights from the crystal structure of
FGFR1 V561M variant (Fig. 2B), MD simulations also depict the change
where the methionine ﬁlls up the hydrophobic pocket adjacent to the
active site stabilizing it (Supplemental Fig. S4). In the active basin of
the FGFR1V561M, the interactions of M561 involve the hydrophobic
residues of the αC helix M535 and L547, the highly conserved residues
surrounding the ATP binding pocket V492, I545 and L630, and the L547
and F642 of the hydrophobic spine. TheαC helix and the E531:K514 salt
bridge are stably formed in both the active and inactive basins of both
FGFR1 and FGFR1V561M kinases. Together, these interactions result in
stabilization of the A-loop in the active conformation and impact on
auto-inhibition due to “molecular brake”.3.4. Gatekeeper Mutation and Oncogenic Variants of FGFR3
FGFR1, FGFR2 and FGFR3 all contribute to the generation of tumours
in diverse cancer types that are in clinical trials for both selective and
non-selective FGFR-inhibitors (Greulich and Pollock, 2011; Wesche
et al., 2011; Sabnis and Bivona, 2013;Dieci et al., 2013). The V561Msub-
stitution in FGFR1 analysed here (Figs. 1, 2 and 3) is unlikely to occur in
FGFR2 as it would require two point mutations; instead, single point
mutations in the codon corresponding to the gatekeeper residue
would result in V564F, V564I or V564L mutations. Taking into account
that subtle differences in the ATP binding pocket (as well as overall dif-
ferences of the structural context) could have a big impact on the inhib-
itor binding, it could be expected that outcomes of such substitutions in
FGFR2 could be different as supported by recent observations for FGFR2
V564I (Byron et al., 2013). In contrast, the FGFR1-equivalent substitu-
tion in FGFR3 (V555M) is highly likely to occur andwas previously iden-
tiﬁed in the context of a cancer cell line (multiple myeloma KMS-11)
dependent on an FGFR3 Y373C driver mutation (Chell et al., 2013).
However, the effects of the gatekeeper mutation on its own, or in com-
bination with other FGFR3 driver mutations, have not been analysed.
Furthermore, in addition to in vitro data, the effectiveness of different
FGFR inhibitors on cells transformed by oncogenic variants of FGFR
with the additional gatekeeper mutation needs to be assessed.aring the theoretical (generated through molecular dynamic simulations) and the exper-
FGFR1WT and FGFRV561M. See also Supplemental Table 3.B. Superposition of apo WT (or-
undWT (marine) and TKI258-bound V561M FGFR1 KD (forest green) (middle panel) are
s shown for theWT (left panel). TKI258 bound toWT FGFR1 KD and V561M FGFR1 KD are
gatekeeper residue and Y 653,654 are indicated. The right panel features superposition of
and M561, and K514 displacement in FGFR1 KD V561M structure. Electron density map
entmolecules inWT FGFR1 KD at the active site are shown as red spheres alongwith elec-
WT FGFR1 KD and FGFR1 KD V561M is shown in the left and middle panel, respectively.
wn for TKI258, gatekeeper residue V/M561 and K514. Solvent molecule interacting with
m is coloured in green. Ball-and-stick representation of WT FGFR1 KD bound PD173074
loured in lime, Y563, V/M561 in black, residues involved in hydrogen bonding interactions
Waals contacts are in orange.
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shows that, as in FGFR1, the gatekeeper mutation resulted in enhanced
activity. Compared to the most potent activating point mutation in
FGFR3, K650E, this increase is less pronounced (kcat/Km comparison)
(Fig. 4A, Supplemental Table S2). Determination of changes in Ki values
for the four selected inhibitors (Fig. 4B) is also in good agreement with
the data obtained for FGFR1V561M(Fig. 1B, Supplemental Table S1). Fur-
thermore, the direct assessment of TKI258 binding to FGFR3 usingNMR is
consistent with the structure of FGFR1 KD/TKI258 complex solved by X-
ray crystallography (Supplemental Fig. S1B). Based on this close similari-
ty, it is expected that the phospho-form (or activated forms) of FGFR3
would also be somewhat less sensitive to TKI258.
The comparison of stable NIH 3T3 cell lines expressing FGFR3 WT,
FGFR3 V555M or FGFR3 K650E variants has shown that the phosphory-
lation of FGFR3 V555M is increased compared to the WT but is not as
high as observed for the activated form FGFR3 K650E (Fig. 4C). Further
analysis of these cell lines revealed that, unlike the oncogenic FGFR3
K650E variant, the FGFR3 V555M gatekeeper on its own lacks potential
to increase growth rate or induce anchorage independent growth and a
transformed phenotype in NIH 3T3 cells (Fig. 4C).
Another recently discovered, clinically important FGFR3 oncogenic
drivers are the FGFR3-TACC3 fusion proteins (Williams et al., 2013;
Singh et al., 2012); one such fusion protein is depicted in Fig. 4D. This
FGFR3-TACC3 protein includes a large portion of the WT FGFR3 IIIb se-
quence covering the entire KD and lacking only a small portion at the
C-terminus that is replaced by TACC3. Importantly, cancer cell lines
(RT112 and RT4, bladder) and transformed cell lines harbouring such fu-
sion proteins have been extensively studied for inhibitor sensitivity both
in culture and in animal models (Lamont et al., 2011; Singh et al., 2012).
NIH 3T3 cells expressing FGFR3-TACC3 fusion protein are selectively
inhibited by FGFR inhibitors such as PD173074 compared to cells
expressing FGFR3 WT that are unaffected (Supplemental Fig. S5A) in
agreement with observations using cancer cell lines (Lamont et al.,
2011). Introduction of the V555M gatekeeper to the FGFR-TACC3 con-
struct retained the general oncogenic properties including the trans-
formed phenotype and higher growth rate of the NIH 3T3 cell line
(Supplemental Fig. S5B).
Treatment of control NIH 3T3 cells with PD173074, AZD4547 or
TKI258 had very little or no effect within the concentration range up
to 1 μM (Fig. 4D, left panel). AP24534 was not included in this study
due to inhibitory effects (over 60% at 1 μM concentration) of this
multi-kinase drug under control condition in this particular cell line.
AP24534 inhibits some non-receptor (ABL, LYN and SYK; IC50 about
0.2–0.4 nM) and receptor tyrosine kinases FGFR, vascular endothelial
growth factor receptor (VEGFR) and PDGFα (IC50 values 1–2.5 nM).
In contrast, TKI258 targets several related tyrosine kinase receptors
[FGFR, FMS-like tyrosine kinase-3 (FLT3), KIT and VGFR with IC50
values within a range of 1–10 nM] (Dieci et al., 2013). The effect of
PD173074, AZD4547 or TKI258 on the FGFR3-TACC3 fusion NIH3T3
cell line reﬂected the Ki values determined using the kinase assay
in vitro, althoughwithin a narrower range. AZD4547wasmost effective,
followed by PD173074 and less inhibitory TKI258 (Fig. 4D, middle
panel). The NIH 3T3 cell line expressing the FGFR3-TACC3 V555M vari-
ant was affected only by TKI258 (Fig. 4D, right panel). Surprisingly,
AZD4547 was completely ineffective in this cell line, contrasting the
binding constants observed in vitro where the gatekeeper mutation
V555M was analysed as the only alteration within the FGFR3 KD (Ki of
about 80 nM). Although further analyses of more FGFR3 variants in a
cellular context would be needed to address such complexity, this ob-
servation is consistent with the previous data showing that KMS-11
cells harbouring FGFR3 Y373C, V555M variant were only marginally
affected by 1 μM AZD4547 and were maintained in the presence of a
closely related AZ8010 compound at the concentration of 3 μM (Chell
et al., 2013). Overall, our ﬁndings, shown in Fig. 4D, highlight the poten-
cy of TKI258 to inhibit oncogenic variants of FGFR3 incorporating the
V555Mmutation.4. Discussion
The combination of experimental and theoretical approaches
applied here provides new insights into the consequences of speciﬁc
substitutions in FGFR1 and FGFR3 for the drug binding and kinase activ-
ity. In particular, our data provide structural and mechanistic insights
into changes that accompany gatekeeper substitutions leading to kinase
activation and their ability to be targeted by some but not all FGFR in-
hibitors. Importantly, the data highlight the potential of TKI258 and
TKI258-like compounds as a second line treatment to anticipated resis-
tance to several compounds currently in clinical use to target FGFR in
cancer.
The activating effect of gatekeeper substitutions on kinase activity
has been documented for several kinases including SRC, ABL and EGFR
using structural and computational methodologies. There are only a
few crystal structures available where the most common threonine
gatekeeper residue is substituted by methionine (SRC T338M, EGFR
T790M and ABL T315I) or isoleucine (SRC T341I) (Getlik et al., 2009;
Zhou et al., 2009; O'Hare et al., 2009; Azam et al., 2008). MD simulations
have been performed for EGFR T790M and together with experimental
evidence show the activating effect on the EGFR kinase (Sutto and
Gervasio, 2013). Furthermore, these previous ﬁndings and our data for
FGFR1V651Mvariant, includingmeasurements of kinases activity, crys-
tallography and MD stimulations (Figs. 1, 2 and 3) reinforce a similar
underlying mechanism. As ﬁrst suggested for SRC T341I (Azam et al.,
2008), the valine tomethionine substitution in FGFR1 leads to exclusion
of water molecules and a re-arrangement of K514 side chain potentiat-
ing the hydrophobic spine (that now includes M651) and facilitates
coordination of ATP by K514 (Fig. 2B and C). MD simulations suggest a
set of further interactions in the active basin of FGFR1V561M and outline
allosteric changes that result in a shift towards the active form, includ-
ing an impact on “molecular brake”, a feature not present in most
other kinases (Supplemental Fig. S4). Furthermore, resistance muta-
tions can have an effect on drug binding not only by direct steric hin-
drance but also by allosterically modulating kinase dynamics as
shown for EGFR T790M (Yun et al., 2008; Wan and Coveney, 2011;
Sutto and Gervasio, 2013); this may also be a contributory factor in
FGFR resistance.
We have shown that the gatekeeper valine to methionine substitu-
tions in FGFR1 and FGFR3 resulted in reduction of sensitivity to selective
inhibitors PD17307 and AZD4547; two other tested inhibitors, AP24534
and TKI258, retained their efﬁcacy (Figs. 1, 2 and 4, Table 1). While the
multi-kinase, type II inhibitor AP24534 (ponatinib) has been speciﬁcally
developed to target the gatekeeper mutation in the BCL-ABL fusion
protein occurring in response to imatinib treatment of chronic myeloid
leukaemia (O'Hare et al., 2009; Choi et al., 2010a), TKI258 (dovitinib)
was originally developed as a novel class of RTK inhibitors targeting
FLT3, KIT, VGFR and some PDGFR members, in addition to FGFR1-3
(Renhowe et al., 2009). TKI258 has been and continues to be tested in
clinical trials including malignancies linked to FGFR genetic alterations
(breast cancer, renal cell carcinoma and bladder cancer) and its other
targets (such as KIT in gastrointestinal stromal tumours/GIST) (Andre
et al., 2013; Konecny et al., 2013; Mazzola et al., 2014; Kang et al.,
2013). Our ﬁndings that TKI258 can inhibit FGFR kinases incorporating
gatekeeper substitutions (Fig. 1, 2 and 4) suggest that it could be also
considered as a second-line treatment following failure of imatinib in
GIST patients because one of the frequent causes of such failure is the
intrinsic resistancemutation in the related KIT target, affecting the gate-
keeper residue (Tamborini et al., 2006).
Our data, including previously unavailable high-resolution crystal
structure of TKI258 bound to a protein kinase, show that TKI258 is a
type I inhibitor and binds to native FGFR1 without causing any structural
alterations (Fig. 2B and C). Similar considerations apply to binding to
FGFR3. When compared to type I FGFR1–3 selective inhibitors and type
II inhibitor AP24534, TKI258 occupies a smaller region conﬁned within
the adenosine-binding pocket (Supplemental Fig. S6). Selective inhibitors
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201T.D. Bunney et al. / EBioMedicine 2 (2015) 194–204PD173074, AZD4547 andNVP-BGJ398 (the latter twounder clinical trials)
share the 3,5-dimetoxy-phenil moiety and as shown for PD173074 and
NVP-BGJ398 have closely overlapping binding pockets (Supplemental
Fig. S6). Interestingly, FGFR1–4 are among only 15 out of 490 human pro-
tein kinases that have valine as the gatekeeper and the selective inhibitors
are likely to involve an interaction with this uncommon residue (for ex-
ample, V561 in FGFR1 interactswith PD173074 andNVP-BGJ398, Supple-
mental Fig. S6). Thus, it is possible that a shared single point mutation
such as gatekeeper replacement would confer some degree of resistance
to all these inhibitors. Despite a weaker binding to a phosphorylated,
active form, more pronounced for the gatekeeper variant, TKI258 retains
its inhibitory activity towards the gatekeeper replacement in FGFR1 and
FGFR3 in vitro and in cells (Figs. 1, 2 and 4). Furthermore, the availability
of the high-resolution crystal structure with TKI258 (Fig. 2B and C) can
guide further modiﬁcations to increase efﬁcacy and selectivity for FGFRwhile retaining activity towards the gatekeeper mutation. Therefore,
TKI258 or its derivatives may provide therapeutic opportunity not only
for patients with genetic alterations in FGFR but also for those with
acquired resistance to several selective FGFR-inhibitors.
Recently, a modiﬁcation of the FGFR-speciﬁc inhibitor PD173074, has
been reported that covalently targets a cysteine residue in the P-loop (Tan
et al., 2014; Huang et al., 2015). The resulting compounds, in particular
FIIN2 and FIIN3, proved effective towards mutations of the gatekeeper
residue in all FGFR receptors (Tan et al., 2014). Compared to TKI258 the
FIIN compounds occupy a space in the binding pocket that is closer to
the side-chain residues of the gatekeeper replacements; however, due
to its irreversible binding capability and additional stabilization FIIN re-
tains efﬁcacy towards these gatekeeper variants (Supplemental Fig. S7).
Further development of FIIN compounds provides an alternative route
towards effective second-line treatments.
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203T.D. Bunney et al. / EBioMedicine 2 (2015) 194–204Comparison of our data obtained using computational methods and
ﬁndings obtained using experimental approaches, based on structural
and biochemical characterisation, shows remarkable consistency
(Figs. 2A and 3). In particular, the computational study (Table 1 and
Supplemental Tables S4 and S7) emphasizes the importance of using
ensemble MD simulations and thermodynamic integration calculations
to overcome the insufﬁciencies of conformational sampling in single
simulations, so as to generate accurate and reproducible results even
in cases (such as binding of TKI258) where the free energy difference
is small. Together with the enhanced sampling (Fig. 3), this methodolo-
gy shows potential for wider application in studies of drug binding and
in assessments of functional and mechanistic impacts of disease muta-
tions. In turn, these approaches can improve the ability to perform
molecular-based patient selection that would assist clinical trials and
subsequent treatment.
In conclusion, compelling evidence supports the role of FGFRs as key
drivers in the pathogenesis of diverse tumour types. Consequently, and
coupled with the absence of any licensed therapeutics, there are inten-
sive ongoing efforts to develop treatments targeting these receptors.
These efforts also recognize the need to address the widespread prob-
lem of emerging resistance to current drugs, including frequent gate-
keeper mutations in receptor tyrosine kinases. We identiﬁed that one
of the drugs currently in clinical trials — TKI258, or its improved deriv-
atives, could be used to target this type of resistance in FGFR and possi-
bly in related targets.We also show that the computational calculations
used here have wider application in assessing the best line of treatment
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